...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Percutaneous interventions on the hemodialysis reliable outflow vascular access device
【24h】

Percutaneous interventions on the hemodialysis reliable outflow vascular access device

机译:血液透析可靠流出血管通路设备的经皮干预

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To determine the outcomes of percutaneous interventions for prolonging the patency of the Hemodialysis Reliable Outflow (HeRO) device. Materials and Methods: Between January 2007 and August 2011, 73 percutaneous interventions were performed on 26 HeRO devices in 25 patients. The graft was implanted in the upper arm with the outflow catheter tip in the superior vena cava or right atrium. Procedural reports, angiographic images, and clinical notes were retrospectively reviewed. The primary and secondary patency rates after intervention were calculated using the Kaplan-Meier method. Results: The mean time from HeRO implantation to initial dysfunction or thrombosis was 171 days. In 60 (82%) procedures, the HeRO device was thrombosed. An intragraft stenosis was the most common lesion identified (59%; n = 43) followed by an arterial anastomosis stenosis identified in 18% (n = 13). In 22% (n = 16) of procedures in which the HeRO device was thrombosed, an underlying cause was not identified after thrombectomy. The 3-, 6-, and 12-month primary patency rates after intervention were 47%, 37%, and 26% for first-time interventions. The secondary patency rates were 80%, 70%, and 64%. The only complication was pulmonary embolism resulting in death 2 days after HeRO thrombectomy. Conclusions: Percutaneous interventions on thrombosed and failing HeRO devices yielded acceptable primary and secondary patency rates after intervention in these patients with few, if any, alternatives for hemodialysis access.
机译:目的:确定经皮介入治疗的结果,以延长血液透析可靠流出(HeRO)设备的开放时间。材料与方法:自2007年1月至2011年8月,对25例患者的26种HeRO设备进行了73次经皮干预。移植物被植入上臂,流出导管尖端位于上腔静脉或右心房。回顾性地回顾了手术报告,血管造影图像和临床记录。干预后的一级和二级通畅率是使用Kaplan-Meier方法计算的。结果:从植入HeRO到开始出现功能障碍或血栓形成的平均时间为171天。在60次(82%)手术中,对HeRO设备进行了血栓形成。移植内狭窄是最常见的病变(59%; n = 43),其次是动脉吻合口狭窄(18%)(n = 13)。在22%(n = 16)的HeRO装置被血栓形成的过程中,血栓切除术后未发现根本原因。首次干预后3、6和12个月的主要通畅率分别为47%,37%和26%。二次通畅率分别为80%,70%和64%。唯一的并发症是肺栓塞,导致HeRO血栓切除术后2天死亡。结论:对这些患者进行介入治疗后,对血栓形成和失效的HeRO装置进行经皮干预可获得可接受的主要和次要通畅率,几乎没有其他血液透析途径可供选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号